Skip to content

Functional Scaffold Transplantation Combined With Epidural Electrical Stimulation for Spinal Cord Injury Repair

Safety and Efficacy of Functional Neural Regeneration Collagen Scaffold Transplantation Combined With Epidural Electrical Stimulation for Spinal Cord Injury Repair

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03966794
Enrollment
9
Registered
2019-05-29
Start date
2019-08-01
Completion date
2021-12-31
Last updated
2019-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury

Brief summary

The study is designed to assess the role of functional neural regeneration collagen scaffold transplantation combined with epidural electrical stimulation in spinal cord injury patients.

Interventions

Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.

COMBINATION_PRODUCTFunctional scaffold & Epidural Electrical Stimulation

Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.

Sponsors

Affiliated Hospital of Logistics University of CAPF
CollaboratorOTHER
Chinese Academy of Sciences
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

The enrolled participants are divided into three categories: 1. Participants had complete functional scaffold transplantation in previous study and had motor functional recovery 2. Participants With Acute Complete SCI: (1) Classification ASIA A, occurring within past 14 days; (2) Completely spinal cord injury at neurological level C4- T12/L1; (3) No serious complications 3. Participants With Chronic Complete SCI: (1) Classification ASIA A, greater than 6 months post injury and no significant further improvement within past 3 months; (2) Completely spinal cord injury at neurological level C4- T12/L1; (3) Peripheral nervous system in good condition; (4) No serious complications Inclusion Criteria For All The Participants 1. Men or non-pregnant women, 18-60 years old 2. Ability and willingness to regular visit to hospital and follow up during the protocol Procedures 3. Accompanied by a family member 4. Signed informed consent

Exclusion criteria

1. Obvious muscle atrophy or fibrosis 2. Decline in peripheral nerve function 3. A current diagnosis of diseases affecting spinal cord injury recovery or rehabilitation training (e.g., brain injury, cerebral hemorrhage, cognitive impairment, other central nervous system diseases) 4. Having serious health problems, (e.g., cardiovascular disease, diabetes, autoimmune diseases, tumors or severe hypertension) or serious complications (e.g. severe bedsores, pulmonary infection, respiratory disorders) 5. Pregnancy or lactation 6. History of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders 7. No family member accompany or can not get in touch with family members 8. Poor compliance, difficult to complete the study 9. Any other conditions that might increase the risk of participants or interfere with the clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Safety and Tolerability assessed by Adverse EventsUp to 6 monthsProportion of patients with postoperative infections and serious adverse events (SAEs) will be assessed by long term follow-up
Change in ASIA Impairment ScaleBaseline, 1, 3 , 6, 12 and 24 months post-treatmentAmerican Spinal Injury Association Impairment Scale of A, B, C, D or E will be assessed before and after transplantation.

Secondary

MeasureTime frame
Change in Somatosensory Evoked Potentials (SSEP) monitoringBaseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Motor Evoked Potentials (MEP) monitoringBaseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in ASIA motor scoreBaseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Walking SpeedBaseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Stride lengthBaseline, 1, 3 , 6, 12 and 24 months post-treatment
Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI)Baseline, 1, 3 , 6, 12 and 24 months post-treatment
Change in Functional Independence Measure (FIM)Baseline, 1, 3 , 6, 12 and 24 months post-treatment

Countries

China

Contacts

Primary ContactGuang Han
hanguang2006@126.com86-22-60577133

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026